Animal models of chemotherapy-evoked painful peripheral neuropathies |
| |
Authors: | Nicolas Authier David Balayssac Fabien Marchand Bing Ling Aude Zangarelli Juliette Descoeur François Coudore Emmanuel Bourinet Alain Eschalier |
| |
Institution: | (1) Program in Molecular Neuroscience, Mayo Graduate School, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA;(2) Department of Neuroscience, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA;(3) Department of Neurology, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA;(4) Division of Medical Oncology, Mayo Clinic, College of Medicine, Rochester, MN 55905, USA;(5) Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA |
| |
Abstract: | This review examines recent preclinical research on toxic peripheral neuropathy and potential therapeutic developments. Chemotherapy-induced
peripheral neurotoxicity is a major clinical problem because it represents the dose-limiting side effects of a significant
number of antineoplastic drugs. Patients are unable to complete full or optimal treatment schedules. The incidence of chemotherapy-induced
peripheral neuropathy varies depending on the drugs and schedules used, and this can be quite high, particularly when neurophysiological
methods are used to make a diagnosis. However, even when chemotherapy-induced peripheral neuropathy is not a dose-limiting
side effect, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. As such, improved
understanding of the pathophysiology of chemotherapy-induced neurotoxicity need for animal models is clinically relevant and
will assist in the development of future neuroprotective strategies and also in the design of novel chemotherapies with improved
toxicity profiles. In this review, the features of animal models of chemotherapy-induced painful neuropathy developed for
20 years, due to the administration of the most widely used drugs, such as platinum drugs, taxanes, and vinca alkaloids, will
be discussed. In a second part, data available on neuroprotectants and treatment strategies, evaluated using these previous
animal models in the attempt to prevent neuropathic pain, will be summarized. |
| |
Keywords: | |
本文献已被 ScienceDirect SpringerLink 等数据库收录! |
|